Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

N-Acetylcysteine for Pediatric Trichotillomania

Phase 2

Completed

Conditions: Trichotillomania
Hair Pulling

Interventions: Drug: N-Acetylcysteine
Drug: Placebo

First Posted Date: 2009-10-12

Last Posted Date: 2014-07-25

Lead Sponsor: Yale University

Target Recruit Count: 39

Registration Number: NCT00993265

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States

Pilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 4

Completed

Conditions: COPD

Interventions: Drug: N-acetylcysteine
Drug: placebo

First Posted Date: 2009-09-01

Last Posted Date: 2012-07-03

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 12

Registration Number: NCT00969904

Locations: 🇧🇪
University Hospital Antwerp, Edegem, Antwerp, Belgium

N-Acetylcysteine in Severe Acute Alcoholic Hepatitis

Phase 3

Completed

Conditions: Alcoholic Hepatitis

Interventions: Drug: placebo
Drug: N-Acetylcysteine

First Posted Date: 2009-08-20

Last Posted Date: 2009-08-20

Lead Sponsor: Erasme University Hospital

Target Recruit Count: 44

Registration Number: NCT00962442

Locations: 🇧🇪
Erasme University Hospital, Brussels, Belgium

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

Phase 4

Terminated

Conditions: Acute Liver Failure
Fulminant Hepatic Failure

Interventions: Drug: N-acetylcysteine

First Posted Date: 2009-05-11

Last Posted Date: 2020-06-01

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 255

Registration Number: NCT00896025

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Michigan Medical Center, Ann Arbor, Michigan, United States

and more 18 locations

Impact of N-Acetylcysteine on Oxidative Stress and Renal Function in Deceased Kidney Transplant Recipients

Not Applicable

Completed

Conditions: Deceased Kidney Transplantation

Interventions: Drug: N-acetylcysteine

First Posted Date: 2009-02-26

Last Posted Date: 2009-03-02

Lead Sponsor: University of Sao Paulo

Registration Number: NCT00851708

Locations: 🇧🇷
Clinics Hospital, University of Sao Paulo, Medical School, São Paulo, Brazil

N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

Phase 2

Completed

Conditions: Contrast Induced Nephropathy
Critically Ill

Interventions: Drug: D5W Placebo
Drug: N-acetylcysteine

First Posted Date: 2009-01-27

Last Posted Date: 2009-01-27

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 45

Registration Number: NCT00830193

Locations: 🇨🇦
London Health Sciences Centre - University Hospital Campus, London, Ontario, Canada
🇨🇦
London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease

Phase 3

Completed

Conditions: Radiocontrast-Induced Nephropathy
Chronic Kidney Disease
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2008-12-16

Last Posted Date: 2008-12-16

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT00808795

Locations: 🇮🇷
Tehran Heart center, Tehran, Iran, Islamic Republic of

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2008-10-20

Last Posted Date: 2024-11-29

Lead Sponsor: State University of New York - Upstate Medical University

Target Recruit Count: 290

Registration Number: NCT00775476

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
VA Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸
St. Luke's University Health Network, Allentown, Pennsylvania, United States

and more 5 locations

N-Acetylcysteine and Smoking Reduction

Phase 2

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2008-09-11

Last Posted Date: 2017-03-23

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 33

Registration Number: NCT00751257

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

The Acetylcysteine for Contrast-Induced Nephropathy Trial

Phase 3

Completed

Conditions: Acute Kidney Failure

Interventions: Drug: Placebo
Drug: Acetylcysteine

First Posted Date: 2008-08-18

Last Posted Date: 2010-07-12

Lead Sponsor: Hospital do Coracao

Target Recruit Count: 2300

Registration Number: NCT00736866

Locations: 🇧🇷
Hospital do Coração, Sao Paulo, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy